Particular Ventures

Particular Ventures is a specialized venture capital firm based in San Francisco, California, exclusively focused on investing in pre-seed and seed stage medical technology companies. Founded by Dr. Ryan Drant, a veteran in healthcare venture capital, the firm aims to support innovative startups developing novel solutions to address significant unmet medical needs. Dr. Drant brings over two decades of experience in the healthcare investment landscape, including 18 years as a General Partner at New Enterprise Associates (NEA), where he notably led investments in more than 30 companies across medical devices and healthcare services.

The firm's investment strategy centers on identifying companies that leverage breakthrough science and technology to create new paradigms in healthcare. Particular Ventures typically makes initial investments ranging from $500,000 to $2,000,000, positioning itself as a key early-stage financial partner for promising medtech ventures. They often take a lead or co-lead position in funding rounds, demonstrating a commitment to significant involvement beyond just capital provision. This hands-on approach is complemented by their preference for taking a board seat, allowing them to actively guide portfolio companies through critical development phases.

Beyond financial backing, Particular Ventures offers strategic guidance and operational support, leveraging Dr. Drant's extensive network and deep industry insights. Their focus on pre-seed and seed stages underscores a belief in nurturing companies from their foundational phases, helping them navigate regulatory pathways, clinical development, and market entry. The firm's targeted approach ensures that portfolio companies benefit from specialized expertise tailored to the unique challenges and opportunities within the medical technology sector.

This specialized focus, combined with the profound experience of its leadership, positions Particular Ventures as a strategic partner for early-stage medtech innovators. Their commitment to leading or co-leading rounds and taking board seats signifies a deep partnership model, aiming to accelerate the development of transformative healthcare solutions.